目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T4719 | Others Endogenous Metabolite | ||
1,4-D-Gulonolactone (D-Gulonic acid γ-lactone) (也称为还原性抗坏血酸,RAA) 是 L-gulono-1,4-lactone oxidoreductase (EC 1.1.3.8)的底物,催化植物和动物中l -抗坏血酸(维生素C)生物合成的最后一步。enzyme L-Gulono-1,4-lactone oxidase 在容易患坏血病、缺乏维生素c的动物(如人类)中缺失。1,4-D-Gulonolactone 存在于人体血液中,并被用作比较运动引起的氧化应激变化的标志物之一。 | |||
T26168 | |||
Rufigallol (AI3-00865) 是一种具有六个羟基的电子缺失的盘状分子,是诱导非平面AIE 分子形成DLC 的良好单元,是一种蒽醌衍生物。Rufigallol 诱导获得了DLC 特性,而TPE 基团的引入使分子结构在聚集状态下具有良好的荧光。Rufigallol 在体外的显著的协同抗疟作用,在体内与维生素C 和酮类化合物一起使用具有协同作用并显示出抗疟活性。 | |||
T13521 | Others | ||
6-O-Acetyldaidzin is an isoflavone glycoside isolated from soybeans. It significantly inhibits lipid peroxidation in rat liver microsome (IC50: 8.2 μM). | |||
T14062 | Others | ||
6-O-Acetylgenistin is an isoflavone glycoside isolated from soybeans. 6-O-Acetylgenistin significantly inhibits lipid peroxidation in rat liver microsome with an IC50 of 10.6 μM[1][2]. | |||
TN1298 | Dehydrogenase | ||
6''-O-Acetylglycitin is a potential nutriceutical, it is also a potent LDH inhibitor. | |||
T11645 | Others | ||
Impurity C of Calcitriol是 Calcitriol 的杂质。Impurity C of Calcitriol 可用于合成维生素D3。 | |||
T4917 | Endogenous Metabolite | ||
Dehydroascorbic acid ((L)-Dehydroascorbic acid) 是维生素 C 的氧化型,能够透过血脑屏障,对中风具有有效的脑保护作用。 | |||
T76101 | |||
Ascorbate oxidase(即维生素 C 氧化酶),作为一种氧化还原酶,在细胞外基质中的氧化还原调节中起作用。该酶催化抗坏血酸与氧之间的反应,生成脱氢抗坏血酸。 | |||
T82797 | |||
C5aR1 antagonist peptide 是一种源自C5a (趋化因子补体片段5过敏毒素) C末端的生物活性线性肽。它能在人和大鼠的C5a受体上阻断C5a的结合,对于细胞免疫反应的触发起着关键作用。C5a的过度表达与多种免疫炎性疾病如关节炎、阿尔茨海默病、囊性纤维化和系统性红斑狼疮等有着密切关联。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPK-01450 | HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01451 | HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01456 | HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|